Article
Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.
Cancer letters - 1 Oct 2017
Tong Christy W S, Wu William K K, Loong Herbert H F, Cho William C S, To Kenneth K W
Abstract excerpt
The discovery of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) has led to unprecedented clinical response in a subset of lung cancer patients carrying the sensitizing EGFR mutations (L858R or exon 19 deletion). However, disease progression invariably occurs within a year after the initial TKI treatment, predominantly due to the development of acquired resistance caused by the secondary...
Topics
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Drug Resistance, Neoplasm
- ErbB Receptors
- Humans
- Lung Neoplasms
- Molecular Targeted Therapy
- Mutation
- Protein Kinase Inhibitors